Navidea Biopharmaceuticals to Announce Second Quarter 2015 Financial Results on July 30, 2015
July 22 2015 - 2:56PM
Business Wire
- Conference call with investment community
to follow at 8:30 a.m. EDT -
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced that the Company will report its financial results for
the second quarter 2015, on Thursday, July 30, 2015 prior to a
conference call with the investment community, scheduled at 8:30
a.m. EDT.
Investors and the public are invited to access the live audio
webcast through the link below. Participants who would like to ask
questions during the question and answer session must participate
by telephone also. Participants are encouraged to log-in and/or
dial-in fifteen minutes before the conference call begins. The
webcast replay is expected to be available on our investor website,
http://ir.navidea.com, approximately two to four hours after the
live event.
Event: Navidea Biopharmaceuticals Q2 2015 Financial
Results Conference Call Date/Time: Thursday, July 30, 2015 at 8:30
a.m. EDT Webcast Link:
http://edge.media-server.com/m/p/amn8cqij/lan/en
Dial-in Number – US:
(855) 897-5884
Dial in Number – Int’l: (720) 634-2940 Conference ID Number:
92935833 Replay
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150722006373/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2024 to May 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2023 to May 2024